|
|
|
18.06.25 - 15:36
|
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time....
|
|
|
|
|
17.06.25 - 15:27
|
BioRestorative Announces Share Repurchase Program (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026....
|
|
|
|
|
10.06.25 - 14:03
|
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company....
|
|
|
|
|
|
|
13.05.25 - 15:18
|
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting....
|
|
|
08.05.25 - 22:33
|
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update....
|
|
|
07.05.25 - 15:18
|
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Vice President of Research and Development, Francisco Silva, will present an update on its ongoing Phase 2 clinical trial of BRTX-100 in chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting, taking place May 7 - 10, 2025 in New Orleans, LA....
|
|
|
15.04.25 - 14:33
|
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time....
|
|
|
|
|
|
|
20.03.25 - 21:33
|
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025 (GlobeNewswire EN)
|
|
|
MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its 2024 financial results after market close on Thursday, March 27, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
